Global Biologics CDMO (Contract Development and Manufacturing Organization) Market 2021
The global biologics CDMO (contract development and manufacturing organization) market in terms of revenue is set to grow by US$ 22 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 20.3% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for biologics CDMO (contract development and manufacturing organization). The global biologics CDMO (contract development and manufacturing organization) market is segmented on the basis of type, service, cell culture. By type, it is categorized into gene therapy CDMO (contract development and manufacturing organization), and others. By service, the biologics CDMO (contract development and manufacturing organization) market is divided into drug product, and drug substance. Based on cell culture, the biologics cdmo (contract development and manufacturing organization) market is divided into mammalian, and microbial.
The report has profiled some of the key players of the market such as Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza Group AG, Thermo Fisher Scientific Inc..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the biologics CDMO (contract development and manufacturing organization) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: gene therapy CDMO (contract development and manufacturing organization), and others
Service: drug product, and drug substance
Cell culture: mammalian, and microbial
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the global biologics CDMO (contract development and manufacturing organization) market
Pinpoint growth sectors and trends for investment
Understand what the future of the global biologics CDMO (contract development and manufacturing organization) market looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for biologics CDMO (contract development and manufacturing organization). The global biologics CDMO (contract development and manufacturing organization) market is segmented on the basis of type, service, cell culture. By type, it is categorized into gene therapy CDMO (contract development and manufacturing organization), and others. By service, the biologics CDMO (contract development and manufacturing organization) market is divided into drug product, and drug substance. Based on cell culture, the biologics cdmo (contract development and manufacturing organization) market is divided into mammalian, and microbial.
The report has profiled some of the key players of the market such as Boehringer Ingelheim Biopharmaceuticals GmbH, Lonza Group AG, Thermo Fisher Scientific Inc..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the biologics CDMO (contract development and manufacturing organization) market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: gene therapy CDMO (contract development and manufacturing organization), and others
Service: drug product, and drug substance
Cell culture: mammalian, and microbial
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the global biologics CDMO (contract development and manufacturing organization) market
Pinpoint growth sectors and trends for investment
Understand what the future of the global biologics CDMO (contract development and manufacturing organization) market looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. BIOLOGICS CDMO (CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION) MARKET BY TYPE
4.1 Gene Therapy Cdmo (Contract Development And Manufacturing Organization)
4.2 Others
5. BIOLOGICS CDMO (CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION) MARKET BY SERVICE
5.1 Drug Product
5.2 Drug Substance
6. BIOLOGICS CDMO (CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION) MARKET BY CELL CULTURE
6.1 Mammalian
6.2 Microbial
7. COMPANY PROFILES
7.1 Boehringer Ingelheim Biopharmaceuticals GmbH
7.2 Lonza Group AG
7.3 Thermo Fisher Scientific Inc.
8. APPENDIX
8.1 About StrategyHelix
8.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. BIOLOGICS CDMO (CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION) MARKET BY TYPE
4.1 Gene Therapy Cdmo (Contract Development And Manufacturing Organization)
4.2 Others
5. BIOLOGICS CDMO (CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION) MARKET BY SERVICE
5.1 Drug Product
5.2 Drug Substance
6. BIOLOGICS CDMO (CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION) MARKET BY CELL CULTURE
6.1 Mammalian
6.2 Microbial
7. COMPANY PROFILES
7.1 Boehringer Ingelheim Biopharmaceuticals GmbH
7.2 Lonza Group AG
7.3 Thermo Fisher Scientific Inc.
8. APPENDIX
8.1 About StrategyHelix
8.2 Disclaimer
